Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy

Seth E. Karol, Elaine Coustan-Smith, Xueyuan Cao, Sheila A. Shurtleff, Susana C. Raimondi, John K. Choi, Raul C. Ribeiro, Gary V. Dahl, William Paul Bowman, Jeffrey W. Taub, Barbara Degar, Wing Leung, James R. Downing, Ching Hon Pui, Jeffrey E. Rubnitz, Dario Campana, Hiroto Inaba

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Minimal residual disease (MRD) is a strong prognostic factor in children and adolescents with acute myeloid leukaemia (AML) but nearly one-quarter of patients who achieve MRD-negative status still relapse. The adverse prognostic factors among MRD-negative patients remain unknown. We analysed the AML02 study cohort to identify demographic and genetic prognostic factors. Among the presenting features, certain 11q23 abnormalities, such as t(6;11) and t(10;11), acute megakaryoblastic leukaemia without the t(1;22), and age ≥10 years were associated with inferior outcome in patients who had MRD-negative status after either remission induction I or II. By contrast, those with rearrangement of CBF genes had superior outcome. Our study identifies patient populations for whom close post-remission MRD monitoring to detect and treat emerging relapse and adjustment in treatment intensity might be indicated.

Original languageEnglish
Pages (from-to)94-101
Number of pages8
JournalBritish Journal of Haematology
Volume168
Issue number1
DOIs
StatePublished - 1 Jan 2015

Keywords

  • Acute myeloid leukaemia
  • Minimal residual disease
  • Paediatric
  • Prognostic factor

Fingerprint

Dive into the research topics of 'Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy'. Together they form a unique fingerprint.

Cite this